ECHO Diabetes Tele-education for Federally Qualified Health Centers
This study, called ECHO Diabetes FQHC, is looking at how a tele-education program can help primary care providers (PCPs) in Federally Qualified Health Centers (FQHCs) better manage diabetes. The program, called ECHO Diabetes tele-education, involves one-hour online sessions twice a month for six months. The goal is to see if this training helps improve diabetes care, specifically by reducing the number of people with very high HbA1c (a measure of average blood sugar over 2-3 months) and increasing the use of diabetes technology like continuous glucose monitors (CGM) and insulin pumps. This study is observational, meaning researchers are watching what happens rather than giving specific treatments to patients. It aims to include 18 FQHCs that are part of Health Choice Network or Alliance Chicago. The study status is currently unclear.
- Study design
- This is an observational study with a stepped-wedge design, meaning groups of FQHCs will receive the intervention at different times. It plans to involve 18 Federally Qualified Health Centers.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Outcomes will be measured from the start of the study up to 12 months later.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
ECHO Diabetes FQHC
At a glance
Conditions
Where it's being run
2 sites across 2 statesStudy leadership
- Ashby F Walker, Ph.D. · PRINCIPAL_INVESTIGATOR · University of Florida
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Exclusion
What this trial measures
- HEDIS >9% HbA1cFrom baseline to 12-months following
Proportion of FQHC population with \>9% HbA1c
- Technology UseFrom baseline to 12-months following
CGM and Pump Use